Saturday, September 23, 2023
Saturday, September 23, 2023

Clinical Ink Acquires Digital Artefacts

Clinical Ink, a global clinical trial data and technology company and leader in eSource and decentralized clinical trial conduct, today announced its acquisition of Digital Artefacts, a digital endpoint-based technology company with an unrivaled modular platform for complex cognitive, behavioral, and physiological data capture.

“The addition of Digital Artefacts now allows us to drive situational awareness because context matters. Data derived from Digital Artefacts can now increase the richness of our partners’ study data through the convergence of passive and active digital assessments. Their wearables and sensors acumen provides instrumented data collection that complements our existing products and solutions,” said Clinical Ink CEO Ed Seguine. “It continues our commitment to capture data at the source and deliver quantitative insights, empowering our customers to make real-time highly informed decisions.”

The combination of Clinical Ink and Digital Artefacts will provide benefits including:

  • Scientifically validated neurocognitive assessment and research tools (50+ modular, self-administered assessments)
  • Combination of standardized eCOA scales/assessments with novel digital endpoints to produce quantitative patient outcomes
  • Trial specific remote active and passive behavioral assessment, including wearable and sensor data
  • Precision Real-World Data and insights across complex therapeutic areas for which cognition is an endpoint
  • Expertise in creating clinically relevant novel digital endpoint data collection methodologies including voice, movement, behavior, mood, and other real-world measurements
  • Scaled delivery capabilities in logistics, helpdesk, project management, and device acquisition/support for DCTs

These capabilities reinforce Clinical Ink’s reputation as a trusted, global partner in digital source data capture (DDC) and eCOA, furthering the company’s therapeutic-area-specific approach to study design and data certainty from source to submission.

“Our digital endpoint solutions, combined with strong data science, provide expertise that has been foundational with industry recognized partners and top pharma,” noted Joan Severson, co-founder, president, and general manager of Digital Artefacts. “We are very excited to join Clinical Ink and enhance the seamless data collection, cognitive and behavioral assessments, and quantitative outcomes for even the most complex studies.”

With this acquisition, Clinical Ink continues to be the leading partner for decentralized clinical trials with a complete, configurable digital data platform — the only partner equipped to build studies for specific trial needs.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Summus Raises $19.5 Million

Fundraise supports market expansion with Summus emerging as the premier clinical platform to share and access high quality specialty expertise across the continuum of care — serving employers, payers, health systems and physician groups.

Thirona Raises €7,5 Million New Financing to Accelerate the Adoption of its Breakthrough Innovations for Precision Medicine

With this financing, Thirona plans to accelerate the adoption of its break-through innovations for precision medicine.

Levee Medical Secures $4.3M Strategic Investment to Accelerate Clinical Development of the Voro Urologic Scaffold, Designed to Improve Robotic Prostatectomy Outcomes

The trial will evaluate the safety and performance of the Voro Urologic Scaffold as a prophylactic treatment for post-prostatectomy stress urinary incontinence, notes Levee Medical.

Innovac Therapeutics Completes $18 million Series Pre-A Financing To Fund the Development of Its lead Programs and Manufacturing Capabilities

The funding represents a strong endorsement of Innovac's technology, mission and vision from a range of industry Investors.

TherageniX and University of Nottingham Awarded £995K Innovate UK Grant to Develop Powdered Gene Therapy for Bone Regeneration

Dr Anandkumar Nandakumar, CEO of TherageniX, commented: “Our mission is to advance treatments in repairing tissue damage and we are grateful for the support from Innovate UK at this early stage. This grant is a testament to the potential of TherageniX’s novel approach to tissue regeneration and will enable us to make great strides in manufacturing our powdered gene therapy.

By using this website you agree to accept Medical Device News Magazine Privacy Policy